STE vs. BDX, DXCM, IDXX, EW, RMD, HOLX, BAX, PODD, TFX, and GMED
Should you be buying STERIS stock or one of its competitors? The main competitors of STERIS include Becton, Dickinson and Company (BDX), DexCom (DXCM), IDEXX Laboratories (IDXX), Edwards Lifesciences (EW), ResMed (RMD), Hologic (HOLX), Baxter International (BAX), Insulet (PODD), Teleflex (TFX), and Globus Medical (GMED). These companies are all part of the "health care equipment" industry.
Becton, Dickinson and Company (NYSE:BDX) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, community ranking, risk, profitability, media sentiment, analyst recommendations and institutional ownership.
Becton, Dickinson and Company received 267 more outperform votes than STERIS when rated by MarketBeat users. Likewise, 62.29% of users gave Becton, Dickinson and Company an outperform vote while only 58.63% of users gave STERIS an outperform vote.
87.0% of Becton, Dickinson and Company shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 0.3% of Becton, Dickinson and Company shares are owned by company insiders. Comparatively, 1.1% of STERIS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
STERIS has a net margin of 6.95% compared to STERIS's net margin of 6.76%. STERIS's return on equity of 13.90% beat Becton, Dickinson and Company's return on equity.
Becton, Dickinson and Company pays an annual dividend of $3.80 per share and has a dividend yield of 1.6%. STERIS pays an annual dividend of $2.08 per share and has a dividend yield of 0.9%. Becton, Dickinson and Company pays out 83.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. STERIS pays out 54.5% of its earnings in the form of a dividend. Becton, Dickinson and Company has increased its dividend for 52 consecutive years and STERIS has increased its dividend for 19 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Becton, Dickinson and Company currently has a consensus target price of $280.13, suggesting a potential upside of 18.02%. STERIS has a consensus target price of $241.60, suggesting a potential upside of 3.78%. Given STERIS's stronger consensus rating and higher probable upside, equities research analysts plainly believe Becton, Dickinson and Company is more favorable than STERIS.
In the previous week, Becton, Dickinson and Company had 8 more articles in the media than STERIS. MarketBeat recorded 20 mentions for Becton, Dickinson and Company and 12 mentions for STERIS. STERIS's average media sentiment score of 0.78 beat Becton, Dickinson and Company's score of 0.73 indicating that Becton, Dickinson and Company is being referred to more favorably in the media.
Becton, Dickinson and Company has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Comparatively, STERIS has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.
Becton, Dickinson and Company has higher revenue and earnings than STERIS. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.
Summary
Becton, Dickinson and Company beats STERIS on 13 of the 21 factors compared between the two stocks.
Get STERIS News Delivered to You Automatically
Sign up to receive the latest news and ratings for STE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
